All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Legend Biotech, Pfizer, Roche, and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
Niels Van de Donk | EHA 2018 | Immunotherapy in myeloma: why, when and how?
Featured:
Niels van de Donk23rd Congress of EHA, 14-17 June 2018, Stockholm, Sweden
Niels Van de Donk
VU Medical Center, Amsterdam, NL
Interview topic: Immunotherapy in myeloma: why, when and how?
For more information and expert opinions in Multiple Myeloma (MM), please visit: www.multiplemyelomahub.com
Immunotherapy in myeloma: why, when and how?
Your opinion matters
HCPs, what do you view as the greatest barrier to the use of belantamab mafodotin combinations in clinical practice?